IRIS
MONTOMOLI, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.099
EU - Europa 15.274
AS - Asia 8.407
SA - Sud America 1.706
AF - Africa 384
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 7
Totale 41.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.817
GB - Regno Unito 4.996
RU - Federazione Russa 2.896
CN - Cina 2.693
SG - Singapore 2.620
IE - Irlanda 1.762
IT - Italia 1.688
BR - Brasile 1.421
VN - Vietnam 970
UA - Ucraina 838
SE - Svezia 781
FR - Francia 770
HK - Hong Kong 708
DE - Germania 649
KR - Corea 459
FI - Finlandia 416
IN - India 264
ZA - Sudafrica 149
BD - Bangladesh 134
CA - Canada 128
AR - Argentina 119
MX - Messico 87
IQ - Iraq 84
NL - Olanda 80
TR - Turchia 68
ES - Italia 65
AT - Austria 63
PL - Polonia 63
JP - Giappone 53
NG - Nigeria 53
CI - Costa d'Avorio 49
ID - Indonesia 42
PK - Pakistan 41
BE - Belgio 39
EC - Ecuador 38
UZ - Uzbekistan 35
MA - Marocco 32
CO - Colombia 29
KE - Kenya 29
CZ - Repubblica Ceca 28
AU - Australia 26
SA - Arabia Saudita 24
VE - Venezuela 24
LT - Lituania 23
JO - Giordania 19
PE - Perù 19
MY - Malesia 18
PH - Filippine 18
PY - Paraguay 18
CL - Cile 16
JM - Giamaica 16
AE - Emirati Arabi Uniti 15
EG - Egitto 15
IL - Israele 15
CH - Svizzera 13
TN - Tunisia 13
UY - Uruguay 13
AZ - Azerbaigian 12
BG - Bulgaria 12
DZ - Algeria 12
IR - Iran 12
OM - Oman 12
HU - Ungheria 10
TH - Thailandia 10
KG - Kirghizistan 9
NP - Nepal 9
AL - Albania 8
CR - Costa Rica 8
KZ - Kazakistan 8
LB - Libano 8
PT - Portogallo 8
DK - Danimarca 7
GR - Grecia 7
LV - Lettonia 7
RO - Romania 7
AM - Armenia 6
BH - Bahrain 6
BO - Bolivia 6
ET - Etiopia 6
KH - Cambogia 6
PA - Panama 6
SN - Senegal 6
BY - Bielorussia 5
CG - Congo 5
GT - Guatemala 5
HN - Honduras 5
LU - Lussemburgo 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
DO - Repubblica Dominicana 4
EU - Europa 4
PR - Porto Rico 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
EE - Estonia 3
GA - Gabon 3
GE - Georgia 3
Totale 41.844
Salva come PNG Salva come JPEG
Città #
Southend 4.623
Dallas 2.254
Dublin 1.743
Fairfield 1.471
Singapore 1.342
Ashburn 1.115
Chandler 987
Santa Clara 821
Moscow 809
Woodbridge 710
Jacksonville 685
Hong Kong 676
Houston 604
Beijing 593
Wilmington 566
Seattle 562
Hefei 558
San Jose 481
Cambridge 470
Siena 440
Seoul 437
Ann Arbor 406
Council Bluffs 336
The Dalles 289
Princeton 282
Los Angeles 265
Ho Chi Minh City 263
Nanjing 229
Lauterbourg 214
Hanoi 197
Helsinki 192
Dong Ket 189
New York 154
Munich 145
Milan 139
Johannesburg 125
San Diego 119
Buffalo 118
San Mateo 118
Boardman 114
São Paulo 108
Lappeenranta 85
Rome 84
Florence 79
Orem 76
Nanchang 74
Bengaluru 73
Redondo Beach 71
Shanghai 63
London 61
Shenyang 55
Nuremberg 53
Chicago 51
Tianjin 51
Abidjan 49
Columbus 49
Frankfurt am Main 49
Mumbai 49
Abuja 48
Phoenix 47
Toronto 47
Warsaw 47
Tokyo 46
Da Nang 45
Baghdad 44
Rio de Janeiro 44
Hebei 42
Changsha 39
Brussels 37
Chennai 37
Montreal 37
Málaga 37
Kunming 36
Vienna 35
Brooklyn 33
Jiaxing 33
Atlanta 32
Amsterdam 31
Stockholm 31
Hangzhou 30
San Francisco 30
Belo Horizonte 29
Guangzhou 29
Haiphong 29
Jinan 29
Norwalk 29
Brasília 27
Denver 27
Tashkent 27
Brescia 25
Dearborn 25
Dhaka 25
Portsmouth 24
Düsseldorf 23
Turku 23
Boston 21
Mexico City 21
Poplar 21
Redwood City 20
Curitiba 19
Totale 28.382
Salva come PNG Salva come JPEG
Nome #
A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses 628
Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014 614
The virucidal potential effects of violet-blue light on influenza D virus 552
How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions 545
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe: Results from the I-MOVE+ project 503
Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains 493
Elimination of congenital rubella: a seroprevalence study of pregnant women and women of childbearing age in Italy 480
Toxoplasma gondii in women of childbearing age and during pregnancy: seroprevalence study in Central and Southern Italy from 2013 to 2017 457
Pertussis over two decades: Seroepidemiological study in a large population of the Siena Province, Tuscany Region, Central Italy 420
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 369
Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2 344
Egg-Independent Influenza Vaccines and Vaccine Candidates 329
Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice 316
Influenza anti-stalk antibodies: Development of a new method for the evaluation of the immune responses to universal vaccine 294
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 292
A method for detection of neuraminidase antibody in serum 284
Flucelvax (Optaflu) for seasonal influenza 272
Challenges in the development of egg-independent vaccines for influenza 270
Emerging influenza strains in the last two decades: A threat of a new pandemic? 260
Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination 259
Age and influenza-specific pre-vaccination antibodies strongly affect influenza vaccine responses in the icelandic population whereas disease and medication have small effects 258
Influenza immunology evaluation and correlates of protection: a focus on vaccines 256
Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season 256
Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses 254
Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine vaxigrip tetra: Preliminary results in children ≥6 months and older adults 252
N. meningitidis and TLR polymorphisms: A fascinating immunomodulatory network 251
Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production 250
Moderate vaccine effectiveness against severe acute respiratory infection caused by a(H1N1)pdm09 influenza virus and no effectiveness against a(H3N2) influenza virus in the 2018/2019 season in Italy 247
A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines 245
An unwanted guest: Neisseria meningitidis–carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence 245
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies 244
Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children 242
Neisseria meningitidis infection: Who, when and where? 240
How much ozone bactericidal activity is compromised by plasma components? 239
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: Awareness warranted for 2017/18 season 239
A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly. 238
Influenza D virus: Serological evidence in the Italian population from 2005 to 2017 236
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice 232
Impact of erythrocyte species on assays for influenza serology 226
Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans 224
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies 224
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses 222
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine 222
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates 221
A Cell Culture (Vero)–Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses 217
Fighting Neisseria meningitidis: past and current vaccination strategies 217
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 217
Cost-benefit evaluation of anti-influenza vaccination in the elderly during two influenza seasons in the Siena district [Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in due stagioni epidemiche a confronto nella provincia di Siena] 214
Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention 212
Validation of a double-color ELISpot assay of IFN-γ and IL-4 production in human peripheral blood mononuclear cells 208
Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines 208
Thymosin-alpha 1 (Zadaxin™) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria™) in hemodialyzed patients: A pilot study 207
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture 206
Measles in pregnancy: a threat for Italian women? 205
CORRELATES OF PROTECTION AND HOST-RELATED MODIFIERS OF THE IMMUNOGENICITY OF INFLUENZA VACCINES: EVIDENCE MAPS AND EVIDENCE GAPS 205
RT-PCR multiplex per l’identificazione simultanea di influenza virus A/H1N1 A/H3N2 e B e Virus Respiratorio Sinciziale di tipo A e B 202
Influenza vaccines: Evaluation of the safety profile 201
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza 199
Retrospective Study Evaluating Seroprevalence of Hepatitis E Virus in Blood Donors and in Swine Veterinarians in Italy (2004) 198
Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge 198
Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period 194
Mapping host-related correlates of influenza vaccine-induced immune response: An umbrella review of the available systematic reviews and meta-analyses 194
Overview of serological techniques for influenza vaccine evaluation: Past, Present and Future 193
Susceptibility to varicella in childbearing age women, Central Italy: is there a need for vaccinating this population group? 192
Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection 192
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 192
Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection 189
A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019? 189
Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy 188
Controllo dell'attività sterilizzante di un nuovo tipo di autoclave per uso odontoiatrico. 188
Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence 187
Safety, tolerability and immunogenicity of a mammalian cell culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial 187
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 186
Chlamydia pneumoniae and angiographically demonstred coronary artery disease in sample population from Italy 185
Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza 184
Vaccination against Hepatitis B - Lenght of protection among populations at risk 183
Expression of sialic acid influenza receptors in red blood cells from avian and mammalian species: an immunological comparative study 182
Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples 182
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 182
Valutazione benefici/costi della vaccinazione antinfluenzale negli anziani 181
Hepatitis A infection in central Tuscany in children and youths 181
Live attenuated influenza vaccine in children induces b-cell responses in tonsils 180
Pre-emptive vaccination against pandemic influenza virus 179
Sea buckthorn bud extract displays activity against cell-cultured Influenza virus 178
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine 177
Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals 177
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols 175
Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses 173
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response 172
International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE 172
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 170
Understanding the dynamics of seasonal influenza in Italy: incidence, transmissibility and population susceptibility in a 9-year period 170
The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants 170
Water and air ozone treatment as an alternative sanitizing technology 170
Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations 170
Detection of antibodies against influenza D virus in swine veterinarians in Italy in 2004 169
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination 169
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples 169
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium 169
Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention 169
Totale 24.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021431 0 0 0 0 0 0 0 0 0 0 0 431
2021/20222.653 236 394 263 233 100 75 115 174 164 214 225 460
2022/20233.333 201 296 402 480 311 666 90 299 344 62 111 71
2023/20242.547 86 75 187 110 101 589 981 75 27 111 38 167
2024/20256.417 160 386 611 352 727 424 221 368 569 286 652 1.661
2025/202614.820 1.271 2.069 2.031 1.866 2.630 611 1.576 475 660 955 625 51
Totale 42.482